- Leading international syndicate led by RA Capital and cornerstoned by founding investor Syncona - Confirms depth of support for clonal neoantigen T cell therapy strategy STEVENAGE, UK, September 3, 2019-– Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces it has closed a £100 million Series B financing led by incoming U.S. investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group.